IRIS
DANESE, Silvio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.366
AS - Asia 9.049
EU - Europa 4.369
SA - Sud America 2.735
AF - Africa 759
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 45
AN - Antartide 1
Totale 42.375
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.974
SG - Singapore 5.698
BR - Brasile 2.378
CN - Cina 1.783
FI - Finlandia 1.018
IE - Irlanda 707
NG - Nigeria 593
DE - Germania 482
FR - Francia 424
VN - Vietnam 407
GB - Regno Unito 321
IT - Italia 307
HK - Hong Kong 283
CA - Canada 261
NL - Olanda 242
SE - Svezia 205
TR - Turchia 146
IN - India 133
AR - Argentina 122
RU - Federazione Russa 110
BE - Belgio 90
BD - Bangladesh 88
IL - Israele 79
MX - Messico 79
PL - Polonia 74
ES - Italia 72
UA - Ucraina 67
EC - Ecuador 61
JP - Giappone 60
IQ - Iraq 59
ZA - Sudafrica 54
CL - Cile 52
RO - Romania 52
AU - Australia 42
ID - Indonesia 42
A2 - ???statistics.table.value.countryCode.A2??? 41
CZ - Repubblica Ceca 33
PY - Paraguay 32
CO - Colombia 31
GR - Grecia 30
UZ - Uzbekistan 29
VE - Venezuela 29
EG - Egitto 28
PK - Pakistan 28
IR - Iran 27
MA - Marocco 23
AE - Emirati Arabi Uniti 22
KR - Corea 21
LT - Lituania 21
AT - Austria 17
NO - Norvegia 16
NP - Nepal 16
SA - Arabia Saudita 16
TN - Tunisia 16
KE - Kenya 15
AZ - Azerbaigian 14
KZ - Kazakistan 14
CH - Svizzera 13
DZ - Algeria 13
PE - Perù 12
JO - Giordania 11
UY - Uruguay 11
MD - Moldavia 10
PT - Portogallo 10
AL - Albania 9
DK - Danimarca 8
DO - Repubblica Dominicana 8
JM - Giamaica 8
KG - Kirghizistan 8
PA - Panama 8
BY - Bielorussia 7
LB - Libano 7
CR - Costa Rica 6
GT - Guatemala 6
MY - Malesia 6
NZ - Nuova Zelanda 6
OM - Oman 6
BO - Bolivia 5
HN - Honduras 5
PS - Palestinian Territory 5
TW - Taiwan 5
BB - Barbados 4
BG - Bulgaria 4
BN - Brunei Darussalam 4
CY - Cipro 4
ET - Etiopia 4
GE - Georgia 4
HU - Ungheria 4
LV - Lettonia 4
SN - Senegal 4
SY - Repubblica araba siriana 4
TT - Trinidad e Tobago 4
EU - Europa 3
KW - Kuwait 3
MO - Macao, regione amministrativa speciale della Cina 3
PH - Filippine 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
BW - Botswana 2
GY - Guiana 2
Totale 42.341
Salva come PNG Salva come JPEG
Città #
Chandler 4.195
Wilmington 4.032
Singapore 1.853
San Mateo 1.633
The Dalles 1.532
Ann Arbor 1.257
Dallas 1.125
Shanghai 1.121
Helsinki 1.014
Ashburn 781
Lawrence 713
Princeton 713
Dublin 703
Leawood 703
Boardman 699
Benin City 589
New York 458
Paris 394
Woodbridge 378
Fairfield 366
Beijing 315
Hong Kong 274
Amsterdam 226
São Paulo 177
London 175
Toronto 171
Columbus 164
Ho Chi Minh City 161
Seattle 157
Los Angeles 126
Norwalk 103
Milan 96
Phoenix 95
San Diego 95
Kocaeli 92
Hanoi 90
Santa Clara 86
Brussels 84
Rio de Janeiro 83
Council Bluffs 82
Belo Horizonte 62
Warsaw 51
Brasília 50
Munich 47
Redwood City 46
Campinas 41
Brooklyn 38
Houston 38
Monmouth Junction 36
Pune 36
Tokyo 36
Falls Church 34
Abbiategrasso 33
Clearwater 33
Moscow 32
Cambridge 29
Curitiba 29
Porto Alegre 28
Atlanta 27
San Francisco 27
Brno 26
Chicago 25
Des Moines 24
Guayaquil 24
Mexico City 24
Tashkent 24
Boston 23
Johannesburg 23
Chennai 22
Naples 22
Guarulhos 21
Montreal 21
Redmond 21
Stockholm 20
Falkenstein 19
Goiânia 19
Las Vegas 19
Salvador 19
Orem 18
Tappahannock 17
Baghdad 16
Fortaleza 16
Frankfurt am Main 16
Jakarta 16
Ottawa 16
Denver 15
Dhaka 15
Nairobi 15
Quito 15
Raleigh 15
Reston 15
Santo André 15
Seoul 15
São José do Rio Preto 15
Asunción 14
Baku 14
Buffalo 14
Duque de Caxias 14
Ankara 13
Anápolis 13
Totale 28.592
Salva come PNG Salva come JPEG
Nome #
Biological agents for ulcerative colitis : Hypes and hopes 291
Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion 234
Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial 174
Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer 130
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations 128
Crohn's disease 127
Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response 126
A Prospective Comparison Between Computerized Tomography (CT) and Magnetic Resonance (MR) in Ileo-Colonic Crohn's Disease: A Single-Center Experience. 124
Budesonide : teaching an old dog new tricks for inflammatory bowel disease treatment 112
The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation 110
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis 107
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 106
Review article: optimal preparation for surgery in Crohn's disease 104
Balanced propofol sedation administered by nonanesthesiologists : the first Italian experience 103
Role of bowel ultrasound as a predictor of surgical recurrence of Crohn's disease 103
A Prospective Comparison Between 1.5t Magnetic Resonance and 3t Magnetic Resonance in Ileo-Colonic Crohn's Disease: A Single Center Experience 102
A PROSPECTIVE, SINGLE CENTER STUDY OF ENDOSCOPIC SUBMUCOSAL DISSECTION OF RECTAL LST LESIONS > 3 CM BY USING AN INNOVATIVE CONCEPT OF INJECTING AND CUTTING: THE WATER-JET HYBRID-KNIFE (ESD-H) 102
A NEW TOOL FOR PRE-COLONOSCOPY DYING OF THE COLONIC MUCOSA WITH ORAL MULTI MATRIX RELEASE TECHNOLOGY (MMX (R))-RELEASED METHYLENE BLUE: A PRELIMINARY STUDY 101
Adalimumab is effective in achieving clinical and endoscopic long-term deep remission : a case report 98
Unique role of junctional adhesion molecule-A in maintaining mucosal homeostasis in inflammatory bowel disease 97
Adalimumab in active ulcerative colitis: A "real-life" observational study 97
Prospective comparison of computed tomography enterography and magnetic resonance enterography for assessment of disease activity and complications in ileocolonic Crohn's disease 97
Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease 97
Intestinal microbiota in inflammatory bowel disease: Friend of foe? 96
Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease 96
A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies 95
Colitis-associated cancer: the dark side of inflammatory bowel disease 94
Anti-adhesion molecule therapies in inflammatory bowel disease: touch and go 94
Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study 93
All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis 93
PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD 93
New insights into inflammatory bowel disease pathophysiology: Paving the way for novel therapeutic targets 92
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial 92
Evolving strategies and goals of treatment in ulcerative colitis 91
Colifagina, a novel preparation of 8 lysed bacteria ameliorates experimental colitis 91
Narrow-band imaging endoscopy to assess mucosal angiogenesis in inflammatory bowel disease: a pilot study 91
Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease 91
Risk of postoperative recurrence and postoperative management of Crohn's disease 90
Laparoscopic Surgery for Recurrent Crohn's Disease 89
Ulcerative Colitis 89
Adalimumab in Crohn's disease : tips and tricks after 5 years of clinical experience 89
A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis 89
Accuracy of a new diagnostic tool in deep infiltrating endometriosis: Positron emission tomography-computed tomography with 16 alpha-[18F]fluoro-17 beta-estradiol 88
Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment 88
Balanced Propofol Sedation (BPS) Administered by Non-Anesthesiologists vs Midazolam Alone for Endoscopic Procedure in Patients With IBD: A Single Center Open-Label Trial 88
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis 88
Internet use among inflammatory bowel disease patients: an Italian multicenter survey 87
New Drug Delivery Systems in Inflammatory Bowel Disease: MMX (TM) and Tailored Delivery to the Gut 87
Second-Generation Corticosteroids for the Treatment of Crohn's Disease and Ulcerative Colitis: More Effective and Less Side Effects? 86
Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease 86
Galectin-2 induces apoptosis of lamina propria T lymphocytes and ameliorates acute and chronic experimental colitis in mice 85
Thrombomodulin-activated protein C-endothelial protein C receptor pathway: A novel anti-inflammatory system in IBD 85
Methotrexate for Corticosteroid- Dependent Ulcerative Colitis: Results of a Placebo Randomized Controlled Trial 85
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study 85
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis 85
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 84
Helicobacter pylori eradication down-regulates matrix metalloproteinase-9 expression in chronic gastritis and gastric ulcer 84
mTOR-Dependent Stimulation of IL20RA Orchestrates Immune Cell Trafficking through Lymphatic Endothelium in Patients with Crohn's Disease 83
Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. 83
Management of IBD during the COVID-19 outbreak: resetting clinical priorities 83
COVID-19 Digestive System Involvement and Clinical Outcomes in a Large Academic Hospital in Milan, Italy 83
Endoscopic flexible treatment of Zenker's diverticulum: a modification of the needle-knife technique 82
Immune regulation by microvascular endothelial cells: Directing innate and adaptive immunity, coagulation, and inflammation 82
IBD Of mice and men-shedding new light on IL-13 activity in IBD 81
Endoscopic mucosal resection for early colorectal neoplasia: pathologic basis, procedures, and outcomes. 81
Adalimumab in ulcerative colitis: Ready for prime time 81
Effect of Immunosuppression on Immune Response to Pneumococcal Vaccine in Inflammatory Bowel Disease: A Prospective Study 81
Emerging biologics in the treatment of inflammatory bowel disease : what is around the corner? 80
VEGF-C-dependent stimulation of lymphatic function ameliorates experimental inflammatory bowel disease 80
JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? 80
WallFlex colonic stent placement for management of malignant colonic obstruction : a prospective study at two centers 80
Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis 80
A PROLONGED FOLLOW-UP ON THE EFFICACY AND SAFETY OF INFLIXIMAB BIOSIMILAR CT-P13 IN IBD ACROSS ITALY: THE PROSIT COHORT 80
Meta-Analysis of the Association Between Anti-Tumour Necrosis Factor Use and Lymphoma Risk in Patients With Inflammatory Bowel Disease: Methodological Considerations 79
Dysregulated intracellular redox equilibrium in intestinal lamina propria T cells (LPT) contributes to mucosal inflammation 79
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients 79
Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn's disease 79
Perception of reproductive health in women with inflammatory bowel disease 79
Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. 79
Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients 78
Impact of Tumour Necrosis Factor Antagonists on Avoiding Surgery in Stricturing Crohn's Disease: A Tertiary Center Real-Life Experience 78
Impact of Medications on Radiologic Disease Activity and Bowel Damage in Crohn's Disease: A Prospective Longitudinal MRI Study 78
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-alpha therapy 78
A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT STUDY ASSESSING THE EFFECTIVENESS OF BUDESONIDE MMX® FOR MILD-TO-MODERATE ULCERATIVE COLITIS 78
The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes 77
Association between Helicobacter pylori CagA-positive strains and ischemic stroke. 77
Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study 77
The bacterial sensor Triggering Receptor Expressed on Myeloid cells 2 (TREM-2) is a crucial pathogenic mediator in inflammatory bowel disease (IBD) 77
Critical role of the CD40-CD40-ligand pathway in regulating mucosal inflammation-driven angiogenesis in inflammatory bowel disease 77
Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease 76
Regulatory T-Cell Therapy for Crohn's Disease: In Vivo Veritas 76
Effect of Oral Administration of Methylene Blue MMx (R) Tablets on Double-Stranded DNA Damage Assessed by gamma H2AX Analysis of Colon Biopsy Samples - A Single Center, Open Label, Safety, Phase II Study 76
Anemia in Inflammatory Bowel Disease: The Opening of Pandora's Box? 75
Surgical rates in the era of biological therapy: up, down or unchanged? 75
Systematic review with network meta-analysis: comparative efficacy and safety of budesonide and mesalazine (mesalamine) for Crohn's disease 75
ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer 75
Adalimumab and Azathioprine Combination Therapy for Crohn's Disease: A Shining Diamond? 75
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis 75
Haematopoietic prolyl hydroxylase-1 deficiency promotes M2 macrophage polarization and is both necessary and sufficient to protect against experimental colitis 75
MFSD2A Promotes Endothelial Generation of Inflammation-resolving Lipid Mediators and Reduces Colitis in Mice 75
Totale 9.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 344.630
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 344.630
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20217.113 0 0 0 0 0 2.221 1.007 529 1.484 982 25 865
2021/20224.321 216 55 132 871 39 48 127 555 391 708 944 235
2022/202310.525 1.608 443 1.060 1.208 899 954 32 942 1.830 867 553 129
2023/20245.142 439 531 1.153 220 179 616 231 276 98 90 425 884
2024/20257.680 223 196 74 214 228 940 358 979 985 1.837 812 834
2025/20267.903 2.913 1.132 1.323 1.821 576 138 0 0 0 0 0 0
Totale 43.093